AU5876399A - Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases - Google Patents

Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases

Info

Publication number
AU5876399A
AU5876399A AU58763/99A AU5876399A AU5876399A AU 5876399 A AU5876399 A AU 5876399A AU 58763/99 A AU58763/99 A AU 58763/99A AU 5876399 A AU5876399 A AU 5876399A AU 5876399 A AU5876399 A AU 5876399A
Authority
AU
Australia
Prior art keywords
integrin
polymorphisms
diagnosis
treatment
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58763/99A
Inventor
John Edward Norris Morten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9820341.7A external-priority patent/GB9820341D0/en
Priority claimed from GBGB9824500.4A external-priority patent/GB9824500D0/en
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of AU5876399A publication Critical patent/AU5876399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
AU58763/99A 1998-09-19 1999-09-15 Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases Abandoned AU5876399A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9820341.7A GB9820341D0 (en) 1998-09-19 1998-09-19 Chemical compounds
GB9820341 1998-09-19
GB9824500 1998-11-10
GBGB9824500.4A GB9824500D0 (en) 1998-11-10 1998-11-10 Chemical compounds
PCT/GB1999/003066 WO2000017393A1 (en) 1998-09-19 1999-09-15 Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases

Publications (1)

Publication Number Publication Date
AU5876399A true AU5876399A (en) 2000-04-10

Family

ID=26314386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58763/99A Abandoned AU5876399A (en) 1998-09-19 1999-09-15 Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases

Country Status (4)

Country Link
EP (1) EP1114183A1 (en)
JP (1) JP2002526090A (en)
AU (1) AU5876399A (en)
WO (1) WO2000017393A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6386906B1 (en) 1998-03-16 2002-05-14 Telefonix Inc Cord management apparatus and method
WO2005014853A1 (en) * 2003-07-28 2005-02-17 Universität Bremen Comparative expression analysis for the identification of genes responsible for phenotypic differences
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162890D0 (en) * 1990-07-06 1990-07-06 Novo Nordisk As POLYPEPTIDE
AU2734197A (en) * 1996-04-19 1997-11-12 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
GB9613112D0 (en) * 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1114183A1 (en) 2001-07-11
JP2002526090A (en) 2002-08-20
WO2000017393A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
AU2815900A (en) Clinical and diagnostic database
GB9925804D0 (en) Biological materials and method useful in the diagnosis and treatment of diseases
AU7896100A (en) Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
HUP0201997A2 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
EP1181057A4 (en) Noninvasive genetic immunization, expression products therefrom, and uses thereof
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
EP0676200A3 (en) Use of eliprodil and of its enantiomers in the preparation of medicaments for the treatment of peripheral neuropathies and or central neurodegenerative diseases.
AU1101901A (en) Human fgf-20 gene and gene expression products
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
AU5876399A (en) Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU5875599A (en) Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
AU5618700A (en) Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
AU5052899A (en) Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU5052599A (en) Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
WO2001011039A3 (en) New sequence variants of the human 1-adrenoreceptor gene and use thereof
AU2003240253A1 (en) Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
AUPQ223999A0 (en) Intracellular feedback controls in the diagnosis and treatment of human disease
AU2003244498A1 (en) Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase